Cargando…

Knockout of LASP1 in CXCR4 expressing CML cells promotes cell persistence, proliferation and TKI resistance

Chronic myeloid leukaemia (CML) is a clonal myeloproliferative stem cell disorder characterized by the constitutively active BCR‐ABL tyrosine kinase. The LIM and SH3 domain protein 1 (LASP1) has recently been identified as a novel BCR‐ABL substrate and is associated with proliferation, migration, tu...

Descripción completa

Detalles Bibliográficos
Autores principales:	Herrmann, Andreas B., Müller, Martha‐Lena, Orth, Martin F., Müller, Jörg P., Zernecke, Alma, Hochhaus, Andreas, Ernst, Thomas, Butt, Elke, Frietsch, Jochen J.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley and Sons Inc. 2020
Materias:	Original Articles
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7077607/ https://www.ncbi.nlm.nih.gov/pubmed/31957290 http://dx.doi.org/10.1111/jcmm.14910

Ejemplares similares

Phosphorylation-Dependent Differences in CXCR4-LASP1-AKT1 Interaction between Breast Cancer and Chronic Myeloid Leukemia
por: Butt, Elke, et al.
Publicado: (2020)

Regulation of matrix metalloproteinases (MMPs) expression and secretion in MDA-MB-231 breast cancer cells by LIM and SH3 protein 1 (LASP1)
por: Endres, Marcel, et al.
Publicado: (2016)

LASP1 is a novel BCR-ABL substrate and a phosphorylation-dependent binding partner of CRKL in chronic myeloid leukemia
por: Frietsch, Jochen J., et al.
Publicado: (2014)

New Frontiers for the Cytoskeletal Protein LASP1
por: Butt, Elke, et al.
Publicado: (2018)

Role of the CXCR4-LASP1 Axis in the Stabilization of Snail1 in Triple-Negative Breast Cancer
por: Subramaniyan, Boopathi, et al.
Publicado: (2020)

Growth effect of tki treatment in childhood CML
por: Jeon, Yeon Jin, et al.
Publicado: (2015)

Lasp-1 Regulates Podosome Function
por: Stölting, Miriam, et al.
Publicado: (2012)

An update on the LIM and SH3 domain protein 1 (LASP1): a versatile structural, signaling, and biomarker protein
por: Orth, Martin F., et al.
Publicado: (2014)

Nuclear localisation of LASP-1 correlates with poor long-term survival in female breast cancer
por: Frietsch, J J, et al.
Publicado: (2010)

Is There a Role for Dose Modification of TKI Therapy in CML?
por: Copland, M.
Publicado: (2019)

Polymethine Dye-Functionalized Nanoparticles for Targeting CML Stem Cells
por: Ernst, Philipp, et al.
Publicado: (2020)

Drug Therapy in the Progressed CML Patient with multi-TKI Failure
por: Haznedaroglu, Ibrahim C.
Publicado: (2015)

SIRT7: an influence factor in healthy aging and the development of age-dependent myeloid stem-cell disorders
por: Kaiser, Alexander, et al.
Publicado: (2020)

Publisher Correction: SIRT7: an influence factor in healthy aging and the development of age-dependent myeloid stem-cell disorders
por: Kaiser, Alexander, et al.
Publicado: (2021)

Monitoring of immunity against leukemia stem cell in CML patients after cessation of TKI
por: Matsushita, Maiko, et al.
Publicado: (2015)

P674: 2ND-LINE PONATINIB IN CHRONIC PHASE CHRONIC MYELOID LEUKEMIA (CML-CP) PATIENTS FAILING OR INTOLERANT TO 1ST-LINE 2ND GENERATION TKI THERAPY: INTERIM ANALYSIS OF THE PROSPECTIVE PONS TRIAL
por: Le Coutre, Philipp, et al.
Publicado: (2023)

Loss of tumor suppressor mir-203 mediates overexpression of LIM and SH3 Protein 1 (LASP1) in high-risk prostate cancer thereby increasing cell proliferation and migration
por: Hailer, Amelie, et al.
Publicado: (2014)

LASP1 in Cellular Signaling and Gene Expression: More than Just a Cytoskeletal Regulator
por: Butt, Elke, et al.
Publicado: (2022)

Aplasia in Chronic Phase CML Post-TKI Therapy: A Management Dilemma
por: Ramdial, Jeremy L., et al.
Publicado: (2019)

Combination of PKCδ Inhibition with Conventional TKI Treatment to Target CML Models
por: Muselli, Fabien, et al.
Publicado: (2021)

Re-balance of memory T cell subsets in peripheral blood from patients with CML after TKI treatment
por: Yao, Danlin, et al.
Publicado: (2017)

The CXCR4-Dependent LASP1-Ago2 Interaction in Triple-Negative Breast Cancer
por: Tilley, Augustus M. C., et al.
Publicado: (2020)

PVR and ICAM-1 on Blast Crisis CML Stem and Progenitor Cells with TKI Resistance Confer Susceptibility to NK Cells
por: Kim, Nayoung, et al.
Publicado: (2020)

The development of dasatinib as a treatment for chronic myeloid leukemia (CML): from initial studies to application in newly diagnosed patients
por: Hochhaus, Andreas, et al.
Publicado: (2013)

The occurrence and management of fluid retention associated with TKI therapy in CML, with a focus on dasatinib
por: Masiello, David, et al.
Publicado: (2009)

Monitoring the Response to Tyrosine Kinase Inhibitor (TKI) Treatment in Chronic Myeloid Leukemia (CML)
por: Haznedaroglu, Ibrahim C.
Publicado: (2014)

Impact of emerging ACA on survival in chronic myeloid leukemia (CML)
por: Hehlmann, Rüdiger, et al.
Publicado: (2022)

Step-in dosing of bosutinib in pts with chronic phase chronic myeloid leukemia (CML) after second-generation tyrosine kinase inhibitor (TKI) therapy: results of the Bosutinib Dose Optimization (BODO) Study
por: Isfort, Susanne, et al.
Publicado: (2023)

Variable Behavior of iPSCs Derived from CML Patients for Response to TKI and Hematopoietic Differentiation
por: Bedel, Aurélie, et al.
Publicado: (2013)

Delayed Diagnosis and Multi-TKI Intolerance: A Case Report of CML Concurrent With COVID-19
por: Luan, Chengxin, et al.
Publicado: (2022)

Selective JAK2/ABL dual inhibition therapy effectively eliminates TKI-insensitive CML stem/progenitor cells
por: Lin, Hanyang, et al.
Publicado: (2014)

PB1904: TRIAL IN PROGRESS: A PHASE III STUDY OF ASCIMINIB VS AN INVESTIGATOR-SELECTED TKI IN PATIENTS WITH NEWLY DIAGNOSED CHRONIC MYELOID LEUKEMIA IN CHRONIC PHASE (CML-CP)
por: Hughes, T., et al.
Publicado: (2022)

The CXCR4-LASP1-eIF4F Axis Promotes Translation of Oncogenic Proteins in Triple-Negative Breast Cancer Cells
por: Howard, Cory M., et al.
Publicado: (2019)

Treosulfan plus fludarabine versus TEAM as conditioning treatment before autologous stem cell transplantation for B-cell Non-Hodgkin lymphoma
por: Frietsch, Jochen J., et al.
Publicado: (2022)

Extra-medullary recurrence of myeloid leukemia as myeloid sarcoma after allogeneic stem cell transplantation: impact of conditioning intensity
por: Frietsch, Jochen J., et al.
Publicado: (2020)

Excellent outcomes of 2G-TKI therapy after imatinib failure in chronic phase CML patients
por: Tiribelli, Mario, et al.
Publicado: (2018)

TKI rotation-induced persistent deep molecular response in multi-resistant blast crisis of Ph+ CML
por: Valent, Peter, et al.
Publicado: (2017)

Evaluation of CML TKI Induced Cardiovascular Toxicity and Development of Potential Rescue Strategies in a Zebrafish Model
por: Cheng, Shan, et al.
Publicado: (2021)

The incidental discovery of a constitutional trisomy 21 mosaicism in an adult female with myelodysplastic/myeloproliferative neoplasm
por: O’Hagan Henderson, Samantha, et al.
Publicado: (2021)

Psychosocial distress in young adults surviving hematological malignancies: a pilot study
por: Wittwer, Andreas, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_o7rpu900bidf228rde4qht1b51